These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 3329122)

  • 1. Prolonged weight loss with dexfenfluramine treatment in obese patients.
    Finer N; Craddock D; Lavielle R; Keen H
    Diabete Metab; 1987; 13(6):598-602. PubMed ID: 3329122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of 6 months therapy with dexfenfluramine in obese patients: studies in the United Kingdom.
    Finer N; Craddock D; Lavielle R; Keen H
    Clin Neuropharmacol; 1988; 11 Suppl 1():S179-86. PubMed ID: 3052816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of dexfenfluramine on eating behavior and body weight of obese patients: results of a field study of Isomeride in Austrian general practice].
    Geyer G; Haidinger G; Francesconi M; Langmayr N; Prager R; Schoberberger R; Toplak H; von Kalckreuth G; Kunze M
    Acta Med Austriaca; 1995; 22(5):95-101; 104-9. PubMed ID: 8651045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dexfenfluramine treatment of obesity: a double blind trial with post trial follow up.
    O'Connor HT; Richman RM; Steinbeck KS; Caterson ID
    Int J Obes Relat Metab Disord; 1995 Mar; 19(3):181-9. PubMed ID: 7780494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy and safety of dexfenfluramine treatment in obese adolescents].
    Małecka-Tendera E; Koehler B; Muchacka M; Wazowski R; Trzciakowska A
    Pediatr Pol; 1996 May; 71(5):431-6. PubMed ID: 8710426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of dexfenfluramine in a weight loss program for obese infertile women.
    Galletly C; Clark A; Tomlinson L
    Int J Eat Disord; 1996 Mar; 19(2):209-12. PubMed ID: 8932560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of dexfenfluramine in obese patients: a multicenter study.
    Enzi G; Crepaldi G; Inelmen EM; Bruni R; Baggio B
    Clin Neuropharmacol; 1988; 11 Suppl 1():S173-8. PubMed ID: 3052815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A multicenter open study of dexfenfluramine in Italy. The efficacy and safety of using dexfenfluramine in treating patients with simple or complicated obesity. The DIMOS Group].
    Enzi G
    Ter Arkh; 1997; 69(5):71-5. PubMed ID: 9235665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical observations on the treatment of obese patients with dexfenfluramine].
    Cairella M; Pisculli M; Petraroli AR; Riganelli S; Saracino A; Siani V
    Clin Ter; 1990 Jun; 133(5):289-97. PubMed ID: 2143712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocrine and metabolic effects of dexfenfluramine in patients with android obesity.
    Ditschuneit HH; Flechtner-Mors M; Dolderer M; Fulda U; Ditschuneit H
    Horm Metab Res; 1993 Nov; 25(11):573-8. PubMed ID: 8288160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Different therapies in the treatment of obesity in hypertensive patients].
    Monego ET; Peixoto Mdo R; Jardim PC; Sousa AL; Braga VL; Moura MF
    Arq Bras Cardiol; 1996 Jun; 66(6):343-7. PubMed ID: 9035450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A close look at fenfluramine and dexfenfluramine.
    Vivero LE; Anderson PO; Clark RF
    J Emerg Med; 1998; 16(2):197-205. PubMed ID: 9543401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Drug therapy of obesity--results of treatment with dexfenfluramine].
    Ivković-Lazar T; Stokić E; Lepsanović L
    Med Pregl; 1990; 43(5-6):232-5. PubMed ID: 2287309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tolerance and acceptability of dexfenfluramine in the long-term treatment of obesity in private practice. ESIM Group].
    Héraïef E
    Rev Med Suisse Romande; 1997 Jan; 117(1):19-24. PubMed ID: 9082531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged surveillance of dexfenfluramine in severe obesity.
    Mathus-Vliegen EM
    Neth J Med; 1993 Dec; 43(5-6):246-53. PubMed ID: 8107932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dexfenfluramine reduces cardiovascular risk factors.
    Bremer JM; Scott RS; Lintott CJ
    Int J Obes Relat Metab Disord; 1994 Apr; 18(4):199-205. PubMed ID: 8044193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination.
    Weintraub M; Hasday JD; Mushlin AI; Lockwood DH
    Arch Intern Med; 1984 Jun; 144(6):1143-8. PubMed ID: 6375610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possible thermogenesis with dexfenfluramine.
    Roongpisuthipong C; Panpakdee O; Boontawee A; Kulapongse S; Tanphaichitr V
    J Med Assoc Thai; 1999 Feb; 82(2):150-9. PubMed ID: 10087722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [International study of the effect of dexfenfluramine in obesity (ISIS): 6 months' results].
    Guy-Grand B; Apfelbaum M; Crepaldi G; Gries A; Lefebvre P; Turner P
    Rev Med Interne; 1989; 10(3):271-7. PubMed ID: 2669089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
    J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.